Adaptimmune Therapeutics trades as part of the healthcare sector and is part of the biotechnology industry. The company CEO is James J. Noble. Adaptimmune Therapeutics along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.
Previous Intraday Performance:
The ADAP shares had a previous change of 1.10% which opened at 3.59 and closed at 3.67. It moved to an intraday high of 3.74 and a low of 3.59.
SeekingAlpha: Adaptimmune teams up with Alpine to develop next-gen cell therapies
Historical Performance:
Over the last five trading days, ADAP shares returned 1.38% and in the past 30 trading days it returned -14.85%. Over three months, it changed -22.08%. In one year it has changed -69.89% and within that year its 52 week high was 14.54 and its 52 week low was 3.51. ADAP stock is 4.56% above its 52 week low.
Our calculations result in a 200 day moving average of 6.57 and a 50 day moving average of 4.24. Right now, ADAP stock is trading -44.10% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Adaptimmune teams up with Alpine to develop next-gen cell therapies
Liquidity:
The company has a market cap of $384.3m with 104.7m shares outstanding and a float of 72.5m shares. Trading volume was 114,216 shares and has experienced an average volume of 365,852 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Adaptimmune Therapeutics was -1.02 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.32.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.24 |
|---|---|---|
| 4th | Qtr 2018 | -0.36 |
| 3rd | Qtr 2018 | 0.06 |
| 2nd | Qtr 2018 | -0.48 |
| 1st | Qtr 2018 | -0.24 |
The next earnings report will be: 05-29-2019
The long-term trend of the EPS is an important number as it indicates the present value of Adaptimmune Therapeutics; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 9.10% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 74.70% of institutional ownership.
The beta was calculated to be 1.48.
SeekingAlpha: Acme United beats by $0.06, revenue in-line
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -51.72%, return on assets is -41.11%, price-to-sales is 7.41 and price-to-book is 1.75.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: ADAP, Adaptimmune Therapeutics, Biotechnology, Healthcare
